Abbott Laboratories ended the fourth quarter with sales growth below Wall Street’s expectations, driven primarily by ongoing ...

The global immunoassay market is projected to expand at a compound annual growth rate (CAGR) of approximately 6–7% over the ...

The company may look to raise about ₹300-400 crore, and the promoters may liquidate some stake for the incoming investor.

Nigeria's pharmaceutical sector is recording growing investor interest and commitments, but local manufacturing continues to lag, ...

This article discusses the best dividend aristocrats right now.

Abbott Laboratories ( ABT) Q4 2025 Earnings Call January 22, 2026 9:00 AM EST Good morning, and thank you for standing by.

Abbott Laboratories (NYSE:ABT) Q4 2025 Earnings Call Transcript January 22, 2026 Abbott Laboratories reports earnings inline with expectations. Reported EPS is $1.5 EPS, expectations were $1.5.

Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%. Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80 and first-quarter 2026 ...

Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025 ...

The manufacturing jobs America thought were gone forever are coming back – and they're arriving at unprecedented velocity, ...

A health care tool for an overlooked public health problemFear of needles is one of health care’s most common, and most ignored, barriers.

A couple who grew up around dogs adopted a "Labrador retriever mix" as their first pup, thinking it was going to be their best choice; however, his behavior didn’t quite match their expectations—and ...